Cargando…

Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes

INTRODUCTION: A second-generation basal insulin analogue insulin glargine 300 U/mL (Gla-300) has been marketed in France since June 2016. This real-world study was designed to assess persistence with Gla-300 and the prevalence of related hypoglycemia requiring hospitalization as compared to first-ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roussel, Ronan, Detournay, Bruno, Boultif, Zahra, Bahloul, Amar, Teissier, Clement, Charbonnel, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376764/ https://www.ncbi.nlm.nih.gov/pubmed/32651837 http://dx.doi.org/10.1007/s13300-020-00874-2

Ejemplares similares

Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France
por: Detournay, Bruno, et al.
Publicado: (2020)

Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study
por: Roussel, Ronan, et al.
Publicado: (2016)

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
por: Gourdy, Pierre, et al.
Publicado: (2019)

The Effectiveness of an App (Insulia) in Recommending Basal Insulin Doses for French Patients With Type 2 Diabetes Mellitus: Longitudinal Observational Study
por: Nevoret, Camille, et al.
Publicado: (2023)

Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database
por: Detournay, Bruno, et al.
Publicado: (2015)

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
por: Pettus, Jeremy, et al.
Publicado: (2019)

Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
por: Boronat, Mauro, et al.
Publicado: (2015)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Frequency and Predictors of Self-Reported Hypoglycemia in Insulin-Treated Diabetes
por: Malkani, Samir, et al.
Publicado: (2017)

The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study
por: Balkau, Beverley, et al.
Publicado: (2017)

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
por: Charbonnel, Bernard, et al.
Publicado: (2017)

Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients
por: Dungan, Kathleen, et al.
Publicado: (2019)

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Histopathological nerve and skeletal muscle changes in rats subjected to persistent insulin-induced hypoglycemia
por: Jensen, Vivi Flou Hjorth, et al.
Publicado: (2015)

Paraneoplastic hypoglycemia in a patient with a malignant solitary fibrous tumor
por: Mohammedi, Kamel, et al.
Publicado: (2014)

Comment on persistent hyperinsulinemic hypoglycemia of infancy
por: Prashanth, G. P., et al.
Publicado: (2013)

Persistent Hypoglycemia in Patient with Hodgkin's Disease
por: Lim, Harold Cinco, et al.
Publicado: (2015)

Lipid biosynthesis enzyme Agpat5 in AgRP-neurons is required for insulin-induced hypoglycemia sensing and glucagon secretion
por: Strembitska, Anastasiya, et al.
Publicado: (2022)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Predictive Modeling of Hypoglycemia Risk with Basal Insulin Use in Type 2 Diabetes: Use of Machine Learning in the LIGHTNING Study
por: Bosnyak, Zsolt, et al.
Publicado: (2019)

A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study
por: Nishimura, Akiko, et al.
Publicado: (2017)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk
por: Choudhary, Pratik, et al.
Publicado: (2011)

An Unusual Case of Persistent Hypoglycemia in Scrub Typhus
por: Arora, Poonam, et al.
Publicado: (2022)

Hypoglycemia frequency and treatment satisfaction in patients receiving insulin analogues for treatment of type 1 diabetes mellitus
por: Berlanda, Gabriela, et al.
Publicado: (2021)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Importance of Insulin Immunoassays in the Diagnosis of Factitious Hypoglycemia
por: Nalbantoğlu Elmas, Özlem, et al.
Publicado: (2014)

The Economic Burden of Insulin-Related Hypoglycemia in Spain
por: Parekh, Witesh, et al.
Publicado: (2017)

Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion
por: Omi, Tsubasa, et al.
Publicado: (2016)

Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization
por: Dalal, Mehul R., et al.
Publicado: (2017)

Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary
por: Anderson, John, et al.
Publicado: (2020)

Clinical outcomes in real‐world patients with type 2 diabetes switching from first‐ to second‐generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study
por: Sullivan, Sean D., et al.
Publicado: (2018)

Persistent hyperinsulinemic hypoglycemia of infancy: An overview of current concepts
por: Goel, Prabudh, et al.
Publicado: (2012)

Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes
por: Groener, Jan Benedikt, et al.
Publicado: (2019)

Basal–Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
por: Okajima, Fumitaka, et al.
Publicado: (2018)

Basal insulin requirement of youth with type 1 diabetes differs according to age
por: Urakami, Tatsuhiko, et al.
Publicado: (2013)

Weight-Based, Insulin Dose–Related Hypoglycemia in Hospitalized Patients With Diabetes
por: Rubin, Daniel J., et al.
Publicado: (2011)

Effect of Naloxon on Counter Insulin Hormone Secretion in Insulin-Induced Hypoglycemia
por: Ju, Yeong Shil, et al.
Publicado: (1987)

Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog
por: Su, Chih-Ting, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s15oiv0um060vku16jrj4jvcki